Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,863Revenue $M25,711Net Margin (%)9.9Z-Score2.5
Enterprise Value $M97,183EPS $2.0Operating Margin %14.4F-Score4
P/E(ttm))46.3Cash Flow Per Share $0Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %10.5Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-31.8ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.8Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 73.612%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 73.612%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 73.612%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 73.612%Sold Out0
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 73.6114%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 73.6114%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 73.6114%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 73.6114%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 73.6136%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 73.6136%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 73.6146%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 73.6146%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 73.6145%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 73.6145%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 73.6155%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 73.6157%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 73.6157%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 73.6157%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 73.6157%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 73.6157%Add 42.7%122,294
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


      More From Other Websites
      Roche Furthers Immunotherapy Program with SP142 Launch Aug 26 2014
      Telegraph Markets Webchat Aug 26 2014
      Merck, Pfizer Combining Drugs In Lung Cancer Study Aug 26 2014
      Warren Buffett throws weight behind Burger King deal Aug 26 2014
      Stock futures hold mild gains amid economic reports Aug 26 2014
      A New Pfizer Inc. Bid For AstraZeneca plc? Aug 26 2014
      The 4 Companies Teaming Up For A New Tool To Fight Cancer Aug 25 2014
      Roche to Boost Respiratory Product Lineup with InterMune Buy Aug 25 2014
      [video] Roche's $8.3 billion deal for InterMune Aug 25 2014
      Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths Aug 24 2014
      Balfour Beatty: The fine line between boldness and foolishness Aug 23 2014
      Ampio Shares Fall as STEP Study on Ampion Gets Delayed Aug 22 2014
      AstraZeneca Updates on PLATO Study Investigation on Brilinta Aug 22 2014
      Lannett Updates on Digoxin Safety Issues, Expands Portfolio Aug 22 2014
      Take Advantage Of The ‘Summer Dip’ With The FTSE 100, AstraZeneca plc & Vodafone Group plc Aug 22 2014
      GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA Aug 21 2014
      Actavis Up on Positive Phase III Ceftazidime-Avibactam Data Aug 21 2014
      Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Aug 21 2014
      Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Aug 21 2014
      Raiffeisen rallies, miners slip: Europe movers Aug 21 2014
      Video: Illumina Partners With Big Pharma Firms Aug 21 2014
      Healthcare stocks lift UK's FTSE 100 Aug 21 2014
      Healthcare stocks lift UK's FTSE 100 Aug 21 2014
      Why AstraZeneca (AZN) Stock Is Higher Today Aug 21 2014
      Healthcare stocks lift UK's FTSE 100 Aug 21 2014
      AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for... Aug 21 2014
      Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer Aug 21 2014
      The Risks Of Investing In AstraZeneca plc Aug 21 2014
      Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease Aug 20 2014
      Ampio's Ampion Positive in Open Label Study, Shares Up Aug 20 2014
      Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study Aug 20 2014
      AstraZeneca and Mitsubishi Tanabe link on diabetes research Aug 20 2014
      US Department Of Justice Ends Investigation Of AstraZeneca Trial Aug 19 2014
      Will The US Block Shire PLC’s Buyout And Prevent A Takeover Of AstraZeneca plc? Aug 19 2014
      U.S. clears AstraZeneca over heart drug trial Aug 19 2014
      AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients... Aug 19 2014
      United States Department of Justice closes investigation into PLATO clinical trial for Brilinta Aug 19 2014
      U.S. clears AstraZeneca over heart drug trial Aug 19 2014
      AstraZeneca plc’s Dividends Are Sliding Aug 18 2014
      U.S. investors switch out of Europe as recovery bet sours Aug 15 2014
      AstraZeneca advances tralokinumab to Phase III in severe asthma Aug 14 2014
      AstraZeneca starts final-stage tests on severe asthma drug Aug 14 2014
      'Victorian disease' gout is still big business Aug 13 2014
      Britain's FTSE boosted by dovish BoE, G4S numbers Aug 13 2014
      GlaxoSmithKline plc Beats AstraZeneca plc And Shire PLC In The Pharmaceuticals Stakes Aug 13 2014
      AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with... Aug 13 2014
      AstraZeneca PLC second quarter and half year results 2014 Jul 31 2014
      AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study Jul 30 2014
      AstraZeneca agrees strategic transaction with Almirall in respiratory disease Jul 30 2014
      Merck 2Q profit more than doubles Jul 29 2014
      Bristol 2Q net drops on lower drug sales, charges Jul 24 2014
      MedImmune and Advaxis partner on immuno-oncology combination clinical trial Jul 22 2014
      AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK Jul 18 2014
      New study aims to rapidly test lung cancer drugs Jun 17 2014
      BofA and Hillshire are big market movers May 27 2014
      Nonprescription Nexium heartburn medicine launches May 27 2014
      AstraZeneca rejects $119 billion offer from Pfizer May 19 2014
      AstraZeneca and AT&T are big market movers May 19 2014
      AstraZeneca board rejects new offer from Pfizer May 19 2014
      Pfizer raises offer, highlighting flurry of deals May 19 2014
      Pfizer ups offer for AstraZeneca again, to $119B May 19 2014
      AstraZeneca fends off Pfizer with new growth plan May 06 2014
      Pfizer 1Q profit drops 15 pct due to lower sales May 05 2014
      Pfizer mulls options after AstraZeneca snubs offer May 05 2014
      Stock futures slide after weak Chinese data May 05 2014
      AstraZeneca rejects sweetened Pfizer takeover bid May 02 2014
      Pfizer sweetens bid for AstraZeneca May 02 2014
      Bristol-Myers profit up 54 pct. on cost cuts, sale Apr 29 2014
      Bank of America, AstraZeneca are big market movers Apr 28 2014
      Pfizer still pursuing AstraZeneca after 2nd rebuff Apr 28 2014
      AstraZeneca shares soar on Pfizer interest Apr 28 2014
      AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K. (Japan) Mar 26 2014
      Forxiga® receives regulatory approval in Japan for the treatment of type 2 diabetes Mar 24 2014
      AstraZeneca proposes appointment of Ann Cairns as Non-Executive Director Mar 20 2014
      AstraZeneca announces sale of Alderley Park site in Cheshire, UK Mar 12 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK